Identification of potential drug targets for erectile dysfunction with single‐cell RNA sequencing: A Mendelian randomization study
Andrology · 2026
DOI: 10.1111/andr.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Andrology, 2026. Verfasst von Bo-Yu Xiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Erectile Dysfunction, Phosphodiesterase 5 Inhibitors. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Clinical Research Fund for Geriatric Diseases Research Center.
Abstract (Originalsprache)
Background
A subset of patients with erectile dysfunction (ED) responds poorly to current pharmacological treatments, largely due to the limited availability of well‐defined therapeutic targets beyond phosphodiesterase 5 inhibitors (PDE5i).
Methods
This study used Mendelian randomization (MR) to identify potential therapeutic targets for ED. Cis‐expression quantitative trait loci (cis‐eQTL) were sourced from the eQTLGen Consortium (31,684 individuals). ED summary statistics were derived from two cohorts (229,980 individuals: 6175 ED cases, 223,805 controls; 95,178 individuals: 1154 ED cases, 94,024 controls). Co‐localization analysis assessed shared single nucleotide polymorphism (SNP) influencing ED risk and gene expression. Drug prediction and molecular docking were utilized to validate the therapeutic potential of the identified drug targets, while single‐cell RNA sequencing (scRNA‐seq, dataset GSE206528) identified relevant cell types.
Results
Two drug targets demonstrated significance across both cohorts and were corroborated by co‐localization analysis. Phenome‐wide association studies (PheWAS) revealed no associations with other traits. Molecular docking analysis indicated strong binding affinities between the drugs and proteins. ScRNA‐seq results showed the target genes are predominantly expressed in endothelial cells (ECs), Schwann Cells (SWCs) and smooth muscle cells (SMCs).
Conclusion
This study highlights two promising ED targets, encouraging future research on ECs and SMCs to advance drug development and improve treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
- Andrology Institute, Xiangya Hospital, Central South University, Changsha, China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
- Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Bo-Yu Xiang, Dong-Jie Li
Förderung
- National Clinical Research Fund for Geriatric Diseases Research Center
Zitieren
APA
Xiang, B. Y., Wen, J., Wang, Y. H., Liu, Z. R., An, J. S., Peng, J. X., Chen, L. X., Ding, J., Wang, G. L., Cheng, Q., & Li, D. J. (2026). Identification of potential drug targets for erectile dysfunction with single‐cell RNA sequencing: A Mendelian randomization study. Andrology. https://doi.org/10.1111/andr.70082
Vancouver
Xiang BY, Wen J, Wang YH, Liu ZR, An JS, Peng JX, et al. Identification of potential drug targets for erectile dysfunction with single‐cell RNA sequencing: A Mendelian randomization study. Andrology. 2026. doi:10.1111/andr.70082
BibTeX
@article{Xiang2026,
author = {Xiang, Bo-Yu and Wen, Jie and Wang, Yun-Hao and Liu, Zhen-Rui and An, Jin-Shun and Peng, Jing-Xuan and Chen, Ling-Xiao and Ding, Jian and Wang, Gui-Lin and Cheng, Quan and Li, Dong-Jie},
title = {Identification of potential drug targets for erectile dysfunction with single‐cell RNA sequencing: A Mendelian randomization study},
journal = {Andrology},
year = {2026},
doi = {10.1111/andr.70082}
}
EUVIMED